Canada
Canada Hepatitis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Virus, Test, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Canada · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US at $1.88 Bn. Canada (this report) at 5.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$200.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $337.8 Mn | — | — |
| 2025 (base) | $355.0 Mn | +$17.2 Mn | — |
| 2026 (forecast) | $373.1 Mn | +$18.1 Mn | +5.1% |
| 2027 (forecast) | $392.2 Mn | +$19.0 Mn | +10.5% |
| 2028 (forecast) | $412.2 Mn | +$20.0 Mn | +16.1% |
| 2029 (forecast) | $433.2 Mn | +$21.0 Mn | +22% |
| 2030 (forecast) | $455.3 Mn | +$22.1 Mn | +28.2% |
| 2031 (forecast) | $478.5 Mn | +$23.2 Mn | +34.8% |
| 2032 (forecast) | $502.9 Mn | +$24.4 Mn | +41.7% |
| 2033 (forecast) | $528.5 Mn | +$25.6 Mn | +48.9% |
| 2034 (forecast) | $555.5 Mn | +$27.0 Mn | +56.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.88 Bn
China
$366.3 Mn
Canada (this report)
$355.0 Mn
Japan
$268.0 Mn
Germany
$189.7 Mn
France
$150.9 Mn
UK
$141.6 Mn
Italy
$106.8 Mn
Brazil
$108.3 Mn
Ecuador
$102.8 Mn
Saudi Arabia
$100.1 Mn
India
$101.6 Mn
Spain
$89.2 Mn
Mexico
$81.5 Mn
Australia
$57.6 Mn
Russia
$53.3 Mn
New Zealand
$48.4 Mn
South Africa
$32.9 Mn
UAE
$23.1 Mn
Egypt
$13.3 Mn
Philippines
$12.0 Mn
Malaysia
$9.0 Mn
Hong Kong
$8.7 Mn
Thailand
$6.0 Mn
Singapore
$5.2 Mn
Kenya
$3.8 Mn
Hepatitis diagnostics detect hepatitis B and C infections and measure virus levels to guide treatment.
Key segments of the hepatitis Diagnostics market include virus (Hepatitis B, Hepatitis C and Hepatitis A) and test (Immunoassays, Molecular Tests and Rapid Tests).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the hepatitis Diagnostics market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the hepatitis Diagnostics market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the hepatitis Diagnostics market.
The hepatitis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hepatitis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Canada.
What doctors and scientists are doing in Hepatitis Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Canada · 2 shared keywords
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada
Canada
Canada
Digital Health · Canada
Healthcare Services · Canada
Healthcare Services · Canada
Pharmaceuticals · Canada
Pharmaceuticals · Canada
Healthcare Services · Canada